Amyloidosis
- PMID: 16409147
- DOI: 10.1146/annurev.med.57.121304.131243
Amyloidosis
Abstract
Amyloidosis is a clinical disorder caused by extracellular deposition of insoluble abnormal fibrils, derived from aggregation of misfolded, normally soluble, protein. About 23 different unrelated proteins are known to form amyloid fibrils in vivo, which share a pathognomonic structure although they are associated with clinically distinct conditions. Systemic amyloidosis, with amyloid deposits in the viscera, blood vessel walls, and connective tissue, is usually fatal and is the cause of about one per thousand deaths in developed countries. This rarity and the variable involvement of different organs and tissues are often responsible for missed or delayed diagnosis, and amyloidosis remains a considerable clinical challenge. However, recent elucidation of important aspects of pathogenesis, as well as developments in diagnosis, monitoring, and treatment, have greatly improved outcomes, especially when patients are managed in specialist centers.
Similar articles
-
Drug Insight: emerging therapies for amyloidosis.Nat Clin Pract Nephrol. 2006 May;2(5):263-70. doi: 10.1038/ncpneph0169. Nat Clin Pract Nephrol. 2006. PMID: 16932439 Review.
-
Pathogenesis, diagnosis and treatment of systemic amyloidosis.Philos Trans R Soc Lond B Biol Sci. 2001 Feb 28;356(1406):203-10; discussion 210-1. doi: 10.1098/rstb.2000.0766. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11260801 Free PMC article. Review.
-
[New trends in the treatment of amyloidosis].Med Clin (Barc). 2012 May 26;138(15):667-72. doi: 10.1016/j.medcli.2011.09.032. Epub 2011 Dec 22. Med Clin (Barc). 2012. PMID: 22197598 Review. Spanish.
-
Renal amyloidosis: current views on pathogenesis and impact on diagnosis.Contrib Nephrol. 2011;169:232-246. doi: 10.1159/000314795. Epub 2011 Jan 20. Contrib Nephrol. 2011. PMID: 21252523
-
Amyloidosis: new strategies for treatment.Int J Biochem Cell Biol. 2003 Dec;35(12):1608-13. doi: 10.1016/s1357-2725(03)00169-9. Int J Biochem Cell Biol. 2003. PMID: 12962700 Review.
Cited by
-
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis.BioDrugs. 2022 Sep;36(5):591-608. doi: 10.1007/s40259-022-00550-w. Epub 2022 Sep 12. BioDrugs. 2022. PMID: 36094752 Free PMC article. Review.
-
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.Int J Mol Sci. 2022 Dec 18;23(24):16145. doi: 10.3390/ijms232416145. Int J Mol Sci. 2022. PMID: 36555787 Free PMC article. Review.
-
Haematology and neurology.J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):334-41. doi: 10.1136/jnnp.2006.092023. J Neurol Neurosurg Psychiatry. 2007. PMID: 17369588 Free PMC article. Review.
-
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19232-7. doi: 10.1073/pnas.0703793104. Epub 2007 Nov 27. Proc Natl Acad Sci U S A. 2007. PMID: 18042730 Free PMC article.
-
New insights and modern treatment of AL amyloidosis.Curr Hematol Malig Rep. 2013 Dec;8(4):291-8. doi: 10.1007/s11899-013-0175-0. Curr Hematol Malig Rep. 2013. PMID: 24026941 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical